Navigation Links
Former Johnson & Johnson Executive Brian Perkins Named Chairman of Puroast® Coffee
Date:5/21/2013

Woodland, CA (PRWEB) May 21, 2013

Puroast® Low Acid Coffee has named former Johnson & Johnson executive Brian Perkins as its Chairman of the Board.

Among the many key positions held by Perkins at Johnson & Johnson during his more than 30-year career was as a member of the Johnson & Johnson Executive Committee, Worldwide Chairman of Consumer Pharmaceuticals & Nutritionals and President of McNeil Consumer Products. At J&J, Perkins helped to develop and build the market for such brands as Splenda®, Lactaid®, Tylenol® and Imodium®. Additionally, Perkins headed up J&J’s Global Marketing Group and sponsorship activities for the Beijing Summer and Turin Winter Olympics as well the company’s FIFA World Cup sponsorship.

Perkins is now an active venture investor, partnering with exceptional entrepreneurs in health/wellness and consumer technology sectors. The Juice Press, a fast growing chain of grab and go juices and 100% organic/raw food and SportsYapper, a social sports company which connects fans while they’re watching a game are two of his investment companies.

As Chairman, Perkins will work closely with Puroast® management in many phases of its operations and planning, including marketing, public relations, brand development, retail channel expansion and strategic initiatives. Perkins’ vast experience in building successful consumer product brands in the health and wellness category is particularly important to Puroast’s operations and growth.

“We are thrilled to have Brian Perkins working with Puroast®," said company CEO, Kerry Sachs. “He is the most-qualified person to help us build market presence and continue our mission -- to introduce the enjoyment of drinking Puroast® Low Acid Coffee to coffee drinkers everywhere.”

Puroast® is 100% coffee that combines a rich, smooth taste with 70% less acid than competing brands. The company is rapidly expanding its distribution and access to the nearly one quarter of US consumers who report irritation from drinking coffee.

”I’m passionate about working with talented entrepreneurs like Kerry Sachs who have exquisite insights into their markets and customers,” said Perkins. “Kerry’s relentless journey to find a better tasting, richer coffee has produced a remarkably great-tasting coffee and his proprietary, pure roasting process has yielded a product with substantial health benefits. I look forward to helping the team make Puroast® the next great coffee brand.”

Puroast® Low Acid Coffee is found in many retailers throughout the U.S., including Wal-Mart and Kroger’s, and is available on line through Amazon.com and at http://www.puroast.com

Read the full story at http://www.prweb.com/releases/2013/5/prweb10752987.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Former Vikings and NFL Greats Tackle Sleep Apnea at Upcoming Minneapolis Event
2. Former Athlete Credits Sports for Surviving Horrible Car Accident and Lengthy Coma
3. Special Needs Spotlight: Former SFMTA Board Member Bruce Oka Receives Treatment with San Francisco Sedation Dentist Dr. David Blende
4. Researchers offer new approach to track former prisoners access to community HIV care
5. New coral reef crustacean described and named after late reggae performer Bob Marley
6. Current and former smokers at risk for recurrent hepatitis post-liver transplantation
7. GW Researcher finds depressive symptoms and suicidal thoughts in former finasteride users
8. MCG faculty member, former hostage returns to Kuwait as Fulbright Scholar
9. Brain Changes Found in Small Study of Former NFL Players
10. Multiple Concussions Could Up Depression Risk in Former NFL Players
11. Workshop Helps Young Performers Approach Auditions with Confidence and Style
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, ... recognized for adherence to the highest standards of trauma, maternity, cancer and chronic ... center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the American ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... ... Coppin Insurance Agency, an insurance and financial planning firm based in Lee ... is embarking on a charity drive with the goal of providing support and donations ... Bank of Southwest Florida works to provide fresh and nutritious food free of charge ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: